Evidence map›Paper›PMID 40076052›Full record

ReviewPolymers2025

Chitosan as a Plurivalent Biopolymer in Nanodelivery Systems.

Marius Gabriel Dabija, Iulia Olaru, Tudor Ciuhodaru, Alina Stefanache, Cozmin Mihai, Ionut Iulian Lungu, Gabriela Calin, Carmen Stadoleanu, Daniela Liliana Damir

Abstract readReview
In one paragraph

Review in Polymers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Amylopectin-Polymers · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marius Gabriel Dabija"Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Iulia OlaruFaculty of Medicine and Pharmacy, "Dunarea de Jos" University, 47 Domneasca Str., 800008 Galati, Romania.ORCID 0009-0005-5673-7639
Tudor CiuhodaruFaculty of Dental Medicine, "Apollonia" University of Iasi, 11 Pacurari Str., 700511 Iasi, Romania.
Alina Stefanache"Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Cozmin MihaiFaculty of Dental Medicine, "Apollonia" University of Iasi, 11 Pacurari Str., 700511 Iasi, Romania.
Ionut Iulian Lungu"Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0009-0005-4803-3746
Gabriela CalinFaculty of Medicine and Pharmacy, "Dunarea de Jos" University, 47 Domneasca Str., 800008 Galati, Romania.ORCID 0000-0002-1893-5109
Carmen StadoleanuFaculty of Dental Medicine, "Apollonia" University of Iasi, 11 Pacurari Str., 700511 Iasi, Romania.
Daniela Liliana Damir"Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: This review study will delve into the potential of chitosan nanoparticles (NPs) as adaptable carriers for targeted drug delivery in different therapeutic areas. Chitosan is a biopolymer derived from chitin that has attracted interest in drug delivery applications because of its high biocompatibility and biodegradability. (2) Methods: A comprehensive literature review was conducted by following a careful systematized protocol for searching databases like PubMed, Google Scholar and ScienceDirect. (3) Results: Chitosan NPs are good drug delivery vehicles, notably for cancer. Studies reveal that doxorubicin-loaded chitosan NPs dramatically enhance toxicity to tumor cells compared to free medicines, yielding tumor suppression rates of up to 60%. Researchers found that chemotherapeutics had an 85% encapsulation efficiency (EE), lowering systemic toxicity. Magnetic and pH-responsive chitosan NPs boost drug accumulation by 63% and apoptosis by 54%. Chitosan also boosts medication retention in the lungs by 2.3×, per pulmonary delivery trials. Chitosan NPs also boost ocular medication bioavailability by 3× and improve nasal absorption by 30%, crossing the blood-brain barrier. For bone regeneration, chitosan scaffolds enhance bone mineral density by 46%, facilitating osteogenesis and healing. (4) Conclusions: NPs made of chitosan provide a solid foundation for improving drug delivery systems; yet there are still issues with material variability, scalability, and meeting regulatory requirements that need fixing. Research into combination treatments, ways to increase their specificity, and ways to optimize these NPs offers promising prospects for the creation of novel therapeutic approaches with the potential to improve patient outcomes.

Indexed as

biopolymerschitosannano-architecturenanodelivery systems

Identifiers

PMID40076052
PMCPMC11902495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.